Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZyVersa Therapeutics Inc. (ZVSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/12/2025: ZVSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.61% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.40M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 0.74 | 52 Weeks Range 0.47 - 6.30 | Updated Date 06/29/2025 |
52 Weeks Range 0.47 - 6.30 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.79% | Return on Equity (TTM) -91.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 227915 | Price to Sales(TTM) - |
Enterprise Value 227915 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.21 | Shares Outstanding 4773460 | Shares Floating 4767537 |
Shares Outstanding 4773460 | Shares Floating 4767537 | ||
Percent Insiders 0.13 | Percent Institutions 7.28 |
Analyst Ratings
Rating 1 | Target Price 20 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ZyVersa Therapeutics Inc.
Company Overview
History and Background
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for renal and inflammatory diseases. Founded to address unmet medical needs, they leverage proprietary technology to develop novel therapeutics.
Core Business Areas
- Phase 2a Renal Disease Program (VAR 200): Development of VAR 200, a cholesterol efflux mediator for treatment of kidney diseases, specifically Focal Segmental Glomerulosclerosis (FSGS). Currently in phase 2a clinical trials. It removes cholesterol from kidney cells. This decreases inflammation and fibrosis.
- Phase 1 Inflammatory Disease Program (VAR 101): Development of VAR 101, an inflammasome ASC inhibitor for treatment of inflammatory diseases, including patients with COVID-19 and Multiple Sclerosis. It works by blocking the inflammasome, reducing inflammation.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure involves research, development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- VAR 200 (FSGS Treatment): VAR 200 is a cholesterol efflux mediator targeting FSGS. Currently in Phase 2a trials, market share is currently N/A. Competitors developing FSGS treatments include Retrophin (now Travere Therapeutics) and Calliditas Therapeutics.
- VAR 101 (Inflammatory Diseases): VAR 101 is an inflammasome ASC inhibitor targeting COVID-19, MS, and other inflammatory diseases. Currently in Phase 1 trials, market share is currently N/A. Competitors developing therapies for inflammatory diseases and COVID-19 include a vast array of pharmaceutical companies such as Pfizer, Roche, and AbbVie.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, driven by innovation and regulatory approvals. Renal and inflammatory diseases represent large and growing markets with significant unmet needs.
Positioning
ZyVersa is positioned as an innovator in the treatment of renal and inflammatory diseases, focusing on novel mechanisms of action and unmet needs. They are a small player trying to disrupt major markets.
Total Addressable Market (TAM)
The TAM for renal and inflammatory disease treatments is in the billions of dollars. ZyVersa is aiming to capture a significant portion of this market through its innovative therapies. The success of VAR 200 and VAR 101 will determine their positioning.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Targeting unmet medical needs
- Experienced leadership team
Weaknesses
- Limited financial resources
- Early-stage clinical development
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Regulatory approvals
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Travere Therapeutics (TVTX)
- Calliditas Therapeutics (CALT)
- Pfizer (PFE)
- Roche (RHHBY)
- AbbVie (ABBV)
Competitive Landscape
ZyVersa faces intense competition from established pharmaceutical companies. Its competitive advantage lies in its novel therapeutic candidates and focus on unmet medical needs. However, it needs to overcome financial and development challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Future growth depends on successful clinical trials and commercialization of its products.
Future Projections: Future projections are based on analyst estimates, which are contingent on clinical trial success and regulatory approvals. Positive results could lead to significant growth.
Recent Initiatives: Recent initiatives include advancing clinical trials for VAR 200 and VAR 101, seeking partnerships, and exploring financing options.
Summary
ZyVersa Therapeutics is a high-risk, high-reward clinical-stage biopharmaceutical company. Its strength lies in its novel therapies targeting unmet medical needs. The company's weaknesses include limited financial resources and early-stage clinical development. They need to successfully navigate clinical trials and secure partnerships to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ZyVersa Therapeutics Inc. website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biopharmaceutical companies is highly speculative and involves significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ZyVersa Therapeutics Inc.
Exchange NASDAQ | Headquaters Weston, FL, United States | ||
IPO Launch date 2022-12-12 | Co-Founder, Chairman, CEO & President Mr. Stephen C. Glover | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.zyversa.com |
Full time employees 7 | Website https://www.zyversa.com | ||
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.